Iadademstat and Gilteritinib for the Treatment of FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia: The Frida Study

被引：0
|
作者：
Fathi, Amir T. [1 ]
Braun, Theodore P. [2 ]
Ambinder, Alexander Joseph [3 ]
Borthakur, Gautam [4 ]
Redner, Robert L. [5 ]
Arevalo, Mabel [6 ]
Gutierrez, Sonia
Limon, Ana [7 ]
Faller, Douglas V. [7 ]
机构：
[1] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA
[2] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA
[3] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[5] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[6] Oryzon Genom, Cornella De Llobregat, Spain
[7] Oryzon Genom, Boston, MA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-189291
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia
    McMahon, Christine M.
    Perl, Alexander E.
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (09) : 841 - 849
  • [2] Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
    Daver, Naval
    Perl, Alexander E.
    Maly, Joseph
    Levis, Mark
    Ritchie, Ellen
    Litzow, Mark
    McCloskey, James
    Smith, Catherine C.
    Schiller, Gary
    Bradley, Terrence
    Tiu, Ramon, V
    Naqvi, Kiran
    Dail, Monique
    Brackman, Deanna
    Siddani, Satya
    Wang, Jing
    Chyla, Brenda
    Lee, Paul
    Altman, Jessica K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (35) : 4048 - +
  • [3] Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia
    McMahon, Christine M.
    Canaani, Jonathan
    Rea, Bryan
    Sargent, Rachel L.
    Qualtieri, Julianne N.
    Watt, Christopher D.
    Morrissette, Jennifer J. D.
    Carroll, Martin
    Perl, Alexander E.
    [J]. BLOOD ADVANCES, 2019, 3 (10) : 1581 - 1585
  • [4] The Frida Study: An Option for Mutated FLT3 Relapsed/Refractory Acute Myeloid Leukemia Patients with a Novel Iadademstat and Gilteritinib Combination Therapy
    Fathi, Amir T.
    Arevalo, Mabel
    Gutierrez, Sonia
    Molero, Antonieta
    Sacilotto, Natalia
    Limon, Ana
    Faller, Douglas, V
    [J]. BLOOD, 2022, 140 : 11755 - 11756
  • [5] Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia
    Fathi, Amir Tahmasb
    Arevalo, Mabel
    Gutierrez, Sonia
    Molero, Antonieta
    Sacilotto, Natalia
    Limon, Ana E.
    Faller, Douglas V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Gilteritinib: A Review in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukaemia
    Connie Kang
    Hannah A. Blair
    [J]. Targeted Oncology, 2020, 15 : 681 - 689
  • [7] Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
    Hosono, Naoko
    Yokoyama, Hisayuki
    Aotsuka, Nobuyuki
    Ando, Kiyoshi
    Iida, Hiroatsu
    Ishikawa, Takayuki
    Usuki, Kensuke
    Onozawa, Masahiro
    Kizaki, Masahiro
    Kubo, Kohmei
    Kuroda, Junya
    Kobayashi, Yukio
    Shimizu, Takayuki
    Chiba, Shigeru
    Nara, Miho
    Hata, Tomoko
    Hidaka, Michihiro
    Fujiwara, Shin-Ichiro
    Maeda, Yoshinobu
    Morita, Yasuyoshi
    Kusano, Mikiko
    Lu, Qiaoyang
    Miyawaki, Shuichi
    Berrak, Erhan
    Hasabou, Nahla
    Naoe, Tomoki
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (11) : 2131 - 2141
  • [8] Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
    Naoko Hosono
    Hisayuki Yokoyama
    Nobuyuki Aotsuka
    Kiyoshi Ando
    Hiroatsu Iida
    Takayuki Ishikawa
    Kensuke Usuki
    Masahiro Onozawa
    Masahiro Kizaki
    Kohmei Kubo
    Junya Kuroda
    Yukio Kobayashi
    Takayuki Shimizu
    Shigeru Chiba
    Miho Nara
    Tomoko Hata
    Michihiro Hidaka
    Shin-Ichiro Fujiwara
    Yoshinobu Maeda
    Yasuyoshi Morita
    Mikiko Kusano
    Qiaoyang Lu
    Shuichi Miyawaki
    Erhan Berrak
    Nahla Hasabou
    Tomoki Naoe
    [J]. International Journal of Clinical Oncology, 2021, 26 : 2131 - 2141
  • [9] Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia
    Kugler, Eitan
    Cohen, Inbar
    Amitai, Irina
    Ram, Ron
    Frisch, Avraham
    Nachmias, Boaz
    Canaani, Jonathan
    Moshe, Yakir
    Krayem, Baher
    Aumann, Shlomzion
    Henig, Israel
    Vainstein, Vladimir
    Shargian, Liat
    Ganzel, Chezi
    Yeshurun, Moshe
    Levi, Itay
    Raanani, Pia
    Akria, Luiza
    Ofran, Yishai
    Shimony, Shai
    Wolach, Ofir
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2024,
  • [10] Gilteritinib for the treatment of patients with FLT3 mutated relapsed or refractory acute myeloid leukemia
    Wang, Eunice S.
    [J]. EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2019, 4 (03): : 105 - 112
12345